226 related articles for article (PubMed ID: 21150188)
21. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
22. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ;
J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin in cancer patients: pros and cons.
Dicato M; Plawny L
Curr Opin Oncol; 2010 Jul; 22(4):307-11. PubMed ID: 20498598
[TBL] [Abstract][Full Text] [Related]
24. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
25. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
Lawler PR; Filion KB; Eisenberg MJ
J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
[TBL] [Abstract][Full Text] [Related]
26. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
27. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
28. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
29. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
30. The role of erythropoiesis-stimulating agents in the treatment of anemia.
Fishbane S
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
[TBL] [Abstract][Full Text] [Related]
31. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
32. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
33. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
34. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
Mundle SD
Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
[TBL] [Abstract][Full Text] [Related]
35. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
36. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
37. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
Tonia T; Bohlius J
Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
[TBL] [Abstract][Full Text] [Related]
39. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
40. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
